Zymeworks Inc. (ZYME) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A reveal several concerning factors: a lack of forward guidance, delays in IND filing, and management's vague responses to critical questions. Additionally, pricing pressures and the need for partnerships indicate potential financial and operational challenges. These factors suggest a negative market sentiment, likely leading to a stock price decline of -2% to -8% over the next two weeks.
Key Financial Performance
Total Revenue $2.4 million for Q1 2026, compared to $27.1 million for Q1 2025, a significant decrease driven mainly by the achievement of nonrecurring clinical milestones in 2025 and continued declines in development support and drug supply revenue from Jazz.
Operating Expenses $49.5 million for Q1 2026, compared to $52.7 million for Q1 2025, a decrease primarily driven by lower third-party program costs following reduced activity on later-stage and discontinued programs, partially offset by increased investment in early-stage clinical and preclinical programs and increased unallocated costs related to leadership transition.
Net Loss $44.2 million for Q1 2026, compared to $22.6 million for Q1 2025, an increase primarily due to a decrease in revenue driven by the nonrecurring clinical milestones earned in Q1 2025.
Cash Resources $403.8 million as of March 31, 2026, compared to $270.6 million as of December 31, 2025, an increase attributed to the anticipated regulatory milestone payments and disciplined capital allocation.
Share Repurchase Program Approximately $95.8 million utilized as of May 6, 2026, to acquire 3,930,734 shares at an average price of $24.37 per share, reflecting a commitment to disciplined capital allocation and enhancing long-term shareholder returns.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Zanidatamab: Progress towards commercialization with a PDUFA date set for August 25, 2026, in the U.S. and an sBLA filing in China for first-line HER2-positive GEA. Potential milestone payments of $250 million from Jazz upon U.S. approval and $15 million from V1 upon China approval.
ZW191: Encouraging Phase I data showing strong antitumor activity in ovarian and endometrial cancers, with disease control rates of 94% and 80%, respectively. Safety profile observed to be manageable.
ZW251: Ongoing Phase I trial exploring GPC3 expression in multiple tumor types, including hepatocellular carcinoma and squamous non-small cell lung cancer.
Pan-RAS ADC Platform: Unveiled at AACR with three preclinical candidates targeting RAS-mutated cancers, including non-small cell lung cancer, pancreatic cancer, and colorectal cancer. Demonstrated promising preclinical efficacy and safety.
Market Expansion for Zanidatamab: Potential approvals in the U.S. and China for HER2-positive GEA, supported by partners Jazz and V1 with established commercial capabilities.
Financial Performance: Total revenue of $2.4 million for Q1 2026, a decrease from $27.1 million in Q1 2025 due to nonrecurring clinical milestones. Operating expenses decreased to $49.5 million from $52.7 million year-over-year.
Cash Position: Strong cash resources of $403.8 million as of March 31, 2026, expected to fund operations beyond 2028, assuming milestone payments and share repurchase execution.
Share Repurchase Program: Utilized $95.8 million of the approved $125 million program to repurchase 3.93 million shares at an average price of $24.37 per share.
R&D and Royalty Integration: Focus on integrating R&D with royalty aggregation to drive long-term value. Continued investment in early-stage clinical and preclinical programs.
Leadership Enhancements: Strengthened leadership team with key appointments, including a new General Counsel from Pfizer, to enhance strategic capital allocation and dealmaking capabilities.
Pipeline Development: Advancing multiple programs, including IND readiness for ZW209 in 2026 and ZW1528 in 2027, while exploring external partnerships for pipeline acceleration.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Decline: Total revenue decreased significantly from $27.1 million in Q1 2025 to $2.4 million in Q1 2026, primarily due to nonrecurring clinical milestones achieved in 2025 and reduced development support and drug supply revenue from Jazz.
Net Loss Increase: Net loss increased from $22.6 million in Q1 2025 to $44.2 million in Q1 2026, driven by the revenue decline and ongoing operational expenses.
Regulatory and Commercialization Risks: The company is dependent on regulatory approvals for zanidatamab in the U.S. and China, with significant milestone payments contingent on these approvals. Delays or denials could adversely impact financial performance.
Pipeline Development Risks: The delay in the IND filing for ZW1528 from 2026 to 2027 highlights potential challenges in advancing the pipeline, including competitive pressures and the need for further understanding of IL-33 biology.
Operational and Leadership Transition Costs: Increased unallocated costs related to leadership transitions and higher salaries and benefits could strain operational budgets.
Market and Competitive Risks: The company faces competitive pressures in the ADC and RAS inhibitor markets, with toxicity and resistance being key challenges for RAS-targeted therapies.
Share Repurchase Program Risks: While the share repurchase program has reduced outstanding shares, it has utilized significant capital ($155.8 million), which could limit resources for other strategic initiatives.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue and Milestone Payments: Zymeworks anticipates near-term milestone payments of $250 million upon U.S. approval for GEA from Jazz and $15 million upon approval in China for GA from V1. Additionally, the company expects increased royalty revenue over time as commercial sales of iHARA grow.
Cash Runway: The company expects its existing cash resources, combined with anticipated regulatory milestone payments of $440 million related to potential approvals of Ziihera and GEA in the U.S., Europe, Japan, and China, to fund operations beyond 2028. This projection excludes additional future milestone payments, royalties, or contributions from future partnerships.
Product Approvals and Launches: The PDUFA date for zanidatamab in the U.S. is set for August 25, 2026, with an sBLA filing completed in China for first-line GEA. These regulatory milestones are expected to drive commercialization and royalty revenues.
Pipeline Development: The company plans to advance its ADC portfolio, including ZW191 and ZW251, with ongoing Phase I trials and preclinical developments. IND for ZW1528 is now expected in 2027, delayed from 2026, to refine clinical development strategies.
Strategic Acquisitions and Partnerships: Zymeworks is actively evaluating potential acquisitions and partnerships to enhance its R&D pipeline and scale capabilities. The company remains disciplined in its approach to ensure alignment with long-term strategic objectives.
Share Repurchase Program: Since 2024, Zymeworks has retired approximately 8.3 million shares, representing over 10% of its common shares outstanding, as part of its share repurchase program. This initiative aims to enhance intrinsic value per share and shareholder returns.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: The company has utilized approximately $95.8 million of the approved $125 million repurchase program to acquire 3,930,734 shares at an average price of $24.37 per share as of May 6, 2026. Since 2024, the company has retired approximately 8.3 million shares through the deployment of roughly $155.8 million in capital for a weighted average repurchase price of approximately $18.70 per share. This represents over 10% of the common shares outstanding. The program is designed to reduce share count and increase shareholder participation in future business economics.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How should we think about the cadence of data for internal pipeline programs in the next 12 months?
A:Management stated that updates on ZW191 were presented at AACR and an abstract was accepted for ESMO GIN in June. They plan to present data at oncology meetings throughout 2026 in a peer-reviewed format. No further forward guidance will be provided until abstracts are accepted.
Q:What is the timing for RAS ADCs to reach the clinic, and will the company pursue early clinical stages of development independently?
A:The company is well-positioned to enter the IND-enabling stage and be ready for clinical testing shortly. However, the balance between internal development and partnerships will influence the timing. No definitive date was provided.
Q:How important is it to include additional tumor types beyond liver cancer in the initial clinical data package for ZW51?
A:Management explained that including additional tumor types like squamous non-small cell lung cancer and germ cell tumors is common in dose escalation studies. They are comfortable with this inclusion due to high unmet needs and expression levels of GPC3 in these tumors.
Q:Why has the IND filing for 1528 been delayed, and does the asset block both oxidized and reduced forms of IL-33?
A:The delay is due to the need to understand data from a positive Phase III study on IL-33 biology. The asset has the potential to block both oxidized and reduced forms of IL-33, and its bispecific format with IL-4 is seen as differentiating.
Q:What criteria were used for selecting the pan-RAS ADC payload, and why was high potency not prioritized?
A:Management clarified that potency was a priority and achieved a high bar. Other factors like bystander activity, pharmacokinetics, and tolerability were also considered. The payload showed impressive activity and tolerability in preclinical models.
Q:Can you translate the NHP safety data dose levels for the pan-RAS ADC to the relative level of payload compared to non-ADC-based pan-RAS?
A:Management focused on the distribution and tolerability profile of the ADC rather than comparing relative payload amounts to small molecules. The ADCs are DAR antibodies, which helps in understanding the dose levels.
Q:What are the implications of MFN pricing headwinds for the ex-U.S. royalty stream for Ziihera?
A:Management acknowledged pricing pressures outside the U.S. but stated that these were expected and factored into their modeling. They did not comment further on Jazz's observations or the regulatory strategy for the second interim analysis for HorRIizON-GEA.
Q:What distinguishes the FR alpha ADC from competitors, and has the RAS data driven incremental partnership interest?
A:The FR alpha ADC shows higher activity, stronger response rates, and a better safety profile compared to competitors. Management is open to partnerships and has active discussions across their R&D portfolio, but no specific details were provided.
Q:What should we expect from the ESMOGIN conference presentation on folate receptor alpha ADC?
A:The presentation will include data on folate receptor alpha expression levels from the Phase I dose escalation study. Data from dose optimization will be presented later when mature.
Q:How does the company decide between making a biparatopic antibody versus not?
A:The decision is based on empirical screening for the best delivery and activity with the payload. Biparatopics are chosen when they provide significantly better internalization and tumor penetration compared to monoclonal antibodies.
Q:What is the development strategy for ZW191, and how does the company balance internal development versus partnerships?
A:Management is encouraged by ZW191's data and has invested in dose optimization cohorts. However, further development will likely require a partner due to the competitive landscape in gynecological tumors.
Q:How does the company determine between oncology and inflammation targets for development?
A:The company focuses on unmet needs and opportunities where their technology can provide superior patient benefits, without predetermining therapeutic areas.
Q:Was the RAS inhibitor payload developed in-house, and what was the process?
A:The initial proof of concept used a RevMed pan-RAS inhibitor, but the company later developed a panel of novel payloads in-house, focusing on properties compatible with ADCs.
Q:What is the development strategy for pan-RAS ADCs, and which tumor types are prioritized?
A:The company aims to target multiple tumor types with ADCs designed for specific tumors. They have not disclosed prioritization but highlighted the high penetrance of PTK7 in RAS-mutated lung cancer as an example.
Q:Review of Unclear Management Responses
A:Management avoided providing specific timelines or definitive answers for the timing of RAS ADCs entering the clinic, the regulatory strategy for the second interim analysis for HorRIizON-GEA, and the prioritization of tumor types for pan-RAS ADCs. Additionally, they did not comment on the relative payload levels of pan-RAS ADCs compared to non-ADC-based pan-RAS inhibitors.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AACR
ADCs
GEA
GPC expression
Phase
RAS ADC
RAS inhibitor
RAS pathway
RD
ZW
activity
approval
candidate
capital
cash
cell lung
combination
control patient
development
dose
expression tumor
inhibition
level
line
lung cancer
milestone
model
molecule
opportunity
payload
portfolio
potential
profile
program
royalty
skin
term
treatment
value
ZYME Transcript
Zymeworks Inc. (ZYME) Q1 2026 Earnings Call Transcript
Unknown5-9
The earnings call summary and Q&A reveal several concerning factors: a lack of forward guidance, delays in IND filing, and management's vague responses to critical questions. Additionally, pricing pressures and the need for partnerships indicate potential financial and operational challenges. These factors suggest a negative market sentiment, likely leading to a stock price decline of -2% to -8% over the next two weeks.
Capstone Copper Corp. (CS:CA) Q4 2025 Earnings Call Transcript
Positive3-2
The earnings call highlights strong financial performance with increased revenue, net income, and EBITDA. Strategic initiatives in expanding copper production and targeting renewable energy markets are promising. The company anticipates revenue growth and improved margins, despite some regulatory and economic risks. Lack of shareholder return plans is a downside, but overall, the positive financial metrics and strategic outlook suggest a favorable stock price reaction.
Zymeworks Inc. (ZYME) Q4 2025 Earnings Call Transcript
Positive3-2
The earnings report shows strong financial performance with 25% revenue growth and a shift to net income, indicating effective cost management. Positive cash flow and strategic initiatives in clinical development and partnerships further support a positive sentiment. Despite no updates on dividends or buybacks, the financial health and strategic outlook are favorable. No significant concerns were raised in the Q&A, reinforcing the positive sentiment.
Zymeworks Inc. (ZYME) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
ZYME Slides
ZYME Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
